Neubase Therapeutics Inc

General ticker "NBSE" information:

  • Sector: Health Care
  • Industry: Biotechnology
  • Capitalization: $2.6M

Neubase Therapeutics Inc does not follow the US Stock Market performance with the rate: -25.3%.

Estimated limits based on current volatility of 2.3%: low 0.37$, high 0.39$

Factors to consider:

  • Earnings for 12 months up through Q4 exceed our estimates

Stock Forecast*

* forecast is subjective and experimental, should not be used for any investment decisions

Long term predictions were made for the period from 2022-09-30 to 2024-09-29

  • 2022-09-30 to 2023-09-30 predicted range: [4.74$, 16.33$]
  • 2023-09-30 to 2024-09-29 predicted range: [3.11$, 10.21$]

Financial Metrics affecting the NBSE estimates:

  • Negative: Non-GAAP EPS of -20.80 <= 0.08
  • Negative: Operating Income to Revenue ratio of -1.00 <= 0.01
  • Negative: negative Net Income
  • Negative: Operating Cash Flow per share of -17.86 <= 0.20
  • Negative: Industry Operating Cash Flow per share (median) of -1.66 <= 0.29
  • Negative: Industry Operating Income to Revenue ratio (median) of -0.98 <= 0.02
  • Negative: 0 < Interest Expense per share of 0.01

Similar symbols

Short-term NBSE quotes

Long-term NBSE plot with estimates

Financial data

YTD 2020-09-30 2021-09-30 2022-09-30
Operating Revenue $0.00MM $0.00MM $0.00MM
Operating Expenses $17.07MM $26.57MM $33.32MM
Operating Income $-17.07MM $-26.57MM $-33.32MM
Non-Operating Income $-0.32MM $1.16MM $-0.46MM
Interest Expense $0.01MM $0.03MM $0.02MM
R&D Expense $6.95MM $14.36MM $21.45MM
Income(Loss) $-17.38MM $-25.41MM $-33.78MM
Taxes $-0.12MM $0.00MM $0.00MM
Profit(Loss) $-17.26MM $-25.41MM $-33.78MM
Stockholders Equity $31.29MM $54.07MM $23.19MM
Assets $34.44MM $64.17MM $32.69MM
Operating Cash Flow $-10.71MM $-18.87MM $-29.01MM
Investing Cash Flow $-0.72MM $-2.56MM $-0.47MM
Financing Cash Flow $33.11MM $42.34MM $-0.26MM
Earnings Per Share* $-17.60 $-18.80 $-21.08

* EPS are Split Adjusted, recent splits may be reflected with a delay.